Researchers Break Decades-Old Bottleneck in Chemotherapy Drug Manufacturing

An international team of researchers has achieved a major breakthrough in the production of doxorubicin, a vital chemotherapy drug. Their study identifies and resolves molecular "bottlenecks" that have hindered the natural production of this drug for over five decades.

Doxorubicin, first approved in the 1970s, is a cornerstone treatment for various cancers including breast cancer, bladder cancer, lymphomas, and carcinomas. More than one million patients receive this therapy annually. However, bacteria naturally produce doxorubicin very inefficiently, forcing the pharmaceutical industry to rely on costly, multi-step semi-synthetic manufacturing processes.

"We have uncovered several independent factors that limit doxorubicin formation," said Keith Yamada, PhD, from the University of Turku in Finland and a lead scientist on the study. "By addressing these bottlenecks, we have applied rational strain engineering to enable cost-effective manufacturing that can meet growing global demand."

New Bacterial Strain Developed to Boost Drug Production

This breakthrough resulted from an extensive international collaboration involving six research laboratories: the University of Turku in Finland, three labs in the United States, and two in Leiden, the Netherlands.

The teams identified three main constraints limiting high-yield doxorubicin production.

First, they pinpointed the natural "biological power supply"—redox partners named Fdx4 and FdR3—that provide the essential electron flow powering the drug-producing enzyme.

Second, they discovered that a protein called DnrV acts as a drug-binding "molecular sponge," sequestering doxorubicin to prevent it from inhibiting the enzyme's production machinery.

Third, using X-ray crystallography, the researchers visualized the enzyme for the first time, revealing that the drug molecule binds in an unfavorable position within the enzyme, explaining the slow reaction rate.

By combining these insights, the team engineered a new bacterial strain that produces 180% more doxorubicin than current industrial standards.

To translate these findings into practical applications, the spin-out company Meta-Cells Oy was established last year at the University of Turku. The company aims to commercialize these advanced technologies for sustainable manufacturing of essential antibiotics and anti-cancer agents. This shift toward fully biosynthetic production promises a cleaner, more reliable supply of life-saving medicines.